Navigation Links
TessArae, LLC and Chinese esoteric laboratory, Kindstar Global, secure partnership for development of genetic tests.
Date:4/25/2013

POTOMAC FALLS, Va., April 25, 2013 /PRNewswire/ -- TessArae®, LLC and Kindstar Global, the largest esoteric reference laboratory in China, have signed a collaboration agreement for the development of a pan-ethnic carrier screen for the Chinese population.  The assay, which will be run in Kindstar's laboratories in China, employs TessArae's targeted sequencing development platform and proprietary bioanalysis software. 

The agreement solidifies a development partnership which allows Kindstar to leverage TessArae's design expertise to create and market its own Laboratory Developed Test (LDT) specific to the Chinese market.  TessArae's development platform combines a highly multiplexed amplification strategy with a standard Affymetrix microarray protocol.  Results are delivered as genomic sequence, automatically generated and analyzed by TessArae's GeneCipher™ algorithms.

Kindstar Founder and CEO, Dr. Shiang Huang said in a statement, "TessArae's development platform is a unique and valuable tool that provides Kindstar near immediate access to key markets with clinically appropriate, sequence-driven diagnostics.   Kindstar is able to capture revenue faster at less cost by partnering with TessArae in the expansion of our test menu."

Dr. Tom Richards , TessArae President and CEO, commented "TessArae's development platform grants our partners the combined benefits of two worlds: the efficiency and predictability of microarrays with the rich specificity of genetic sequencing.  As a result, they can develop market-specific genetics assays much more quickly than alternative approaches.  We are excited to partner with Kindstar in bringing their vision of recessive disease testing to the Chinese market."

Kindstar provides esoteric diagnostic testing services to hospitals and physicians in all Chinese provinces, including more than 3,300 hospitals, among them 930 large leading hospitals, so-called tertiary hospitals. It has laboratories in Beijing, Shanghai, and Wuhan.  Additional company information can be found at www.kindstarglobal.com

TessArae is privately held by a partnership lead by John W. Marriott III of the Marriott hotel family.  TessArae is recognized as the market leader in targeted sequencing applications using a microarray.  Since its inception, the company has helped design 15 custom assays for a wide variety of partners, including worldwide government agencies, academic institutions and commercial reference laboratories. TessArae's targeted sequencing platform has been analytically validated.  Reference laboratories use the TessArae platform to develop their own custom genetics assays.  Additional company information can be found at www.tessarae.com

Financial and other terms of the agreement were not disclosed.


'/>"/>
SOURCE TessArae, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research
2. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
3. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
4. MRIGlobal, DHMRI Align in Strategic Collaboration
5. - Unigene Secures Financing to Extend Operating Runway in Conjunction with Strategic Reorganization -
6. VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
7. Nabsys Secures $20 Million Series D Financing to Support Launch of Semiconductor-Based Single-Molecule Platform for Genomic Analysis
8. Unisense FertiliTech A/S Secures an Additional 20 Million USD in New Capital Investment
9. lifeIMAGE Announces No-Cost Service for Hospitals to Give Patients Secure Access to Medical Imaging, Pledges Support for the Blue Button Initiative
10. Blue Marble Biomaterials Secures Distribution Agreement with SAFC
11. Turning smartphones into secure and versatile keys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, ... data on its oral peptide drug candidates, PTG-100 ... of the European Crohn,s and Colitis Organization (ECCO).  ... Barcelona, Spain from February 15 ... detail preclinical data on Protagonist drug candidates PTG-100 ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, ... focused on venture growth investments in biotechnology and ... Josh Richardson , M.D. to Managing Director. ... companies.  He is a board observer at InfaCare ... Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor Therapeutics, ... clinical-stage biotechnology company developing first-in-class biological therapies for ... it has elected to terminate its license agreement ... receptor agonists, including Cenderitide. "Our decision ... as we prioritize our efforts to advance our ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/19/2017)... and PUNE, India , January 19, 2017 ... Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric ... CAGR of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... security for both public and private sectors. Continue ... ...
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
Breaking Biology News(10 mins):